环磷腺苷葡胺注射液对急性心肌梗死患者血清hs—CRP、NT—proBNP的影响

Effect of Meglumine Adenosine Cyclophosphate injection on serum hs-CRP and NT-proBNP in patients with acute myocardial infarction

目的探讨环磷腺苷葡胺注射液在急性心肌梗死（AMI）患者治疗中的临床价值，以及对血清超敏C反应蛋白（hs—CRP）、氨基末端B型钠尿肽前体（NT—proBNP）的影响。方法选取2015年3月至2016年5月我院收治的90例AMI患者，采用随机数字表法分为研究组、对照组各45例。两组患者均给予溶栓治疗±常规治疗，研究组同时加用环磷腺苷葡胺注射液治疗，对比两组患者的治疗效果。结果研究组ST段回落≥50％、再通率分别为86．67％、84.44％，均高于对照组的66.67％、64．44％，差异具有统计学意义（P〈0.05）。治疗后，研究组cI2．87±0．23、心排血量（5．11±0．49）ml、每搏输出量（66．0±5．1）L／min、LVEF（62．3±4．9）％，均高于对照组的CI2．50±0．26、心排量（4．72±0．45）ml、每搏输出量（60．5±3．8）L／min、LVEF（57．5±5．6）％，差异具有统计学意义（P〈0．05）；研究组血清hs—CRP（5．73±2．20）mg／L、NT—proBNP（251．48±74．02）ng／L、TNF-α（12．61±5．40）μg／L、sICAM-1（89．52±27．45）ng／L，均低于对照组血清hs—CRP（8．40±2．77）mg／L、NT—proBNP（311．33±81．15）ng／L、TNF—α（16．43±4．08）μg／L、sICAM-1（110．05±30．62）ng／L，差异具有统计学意义（P〈0．05）。结论环磷腺苷葡胺注射液治疗AMI，有助于患者心功能恢复，降低炎症反应程度。

Objective To investigate the clinical value of Meglumine Adenosine Cyclophosphate Injection in the treatment of AMI patients and the influence of hs-CRP and NT-proBNP. Methods 90 patients with AMI in our hospital from March 2015 to May 2016 were randomly divided into study group and control group （n=45）, two groups of patients were given thrombolytic therapy ± conventional treatment, the study group was treated with Meglumine Adenosine Cyclophosphate Injection at the same time, compared the treatment effect of the two groups of patients. Results The research group of ST segment was more than 50%, the recanalization rate was 86.67%, 84.44%, were higher than the control group 66.67%, 64.44%, the difference was statistically significant（P〈0.05 ）. After treatment, the study group CI（2.87±0.23）, cardiac output（5.11±0.49）ml, stroke output（66.0±5.1）L/min, and LVEF（62.3±4.9）%, were higher than the control group CI（2.50±0.26）, cardiac output（4.72±0.45）ml, stroke output（60.5±3.8）L/min, LVEF（57.5±5.6）%, the difference was statistically significant（P〈0.05）. The serum hs- CRP of the study group was（5.73±2.20）mg/L, NT-proBNP（251.48±74.02）ng/L, TNF-α（12.61±5.40）μg/L, and sICAM-1（89.52±27.45）ng/L, were lower than the control group, serum hs-CRP（8.40±2.77）mg/L, NT-proBNP （311.33±81.15）ng/L, TNF-α（ 16.43±4.08） μg/L, sICAM-1 （ 110.05±30.62）ng/L, the difference was statistically significant（P〈0.05 ）. Conclusion Meglumine Adenosine Cyclophosphate Injection in the treatment of patients with AMI can help the recovery of cardiac function, reduce the level of inflammatory response, and has a positive effect on the treatment of AMI patients.